9-37428581-C-T

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2

The ENST00000493368.5(GRHPR):​n.559C>T variant causes a non coding transcript exon change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0113 in 1,579,830 control chromosomes in the GnomAD database, including 135 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).

Frequency

Genomes: 𝑓 0.0086 ( 8 hom., cov: 33)
Exomes 𝑓: 0.012 ( 127 hom. )

Consequence

GRHPR
ENST00000493368.5 non_coding_transcript_exon

Scores

2

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts B:5

Conservation

PhyloP100: -0.0500

Publications

1 publications found
Variant links:
Genes affected
GRHPR (HGNC:4570): (glyoxylate and hydroxypyruvate reductase) This gene encodes an enzyme with hydroxypyruvate reductase, glyoxylate reductase, and D-glycerate dehydrogenase enzymatic activities. The enzyme has widespread tissue expression and has a role in metabolism. Type II hyperoxaluria is caused by mutations in this gene. [provided by RefSeq, Jul 2008]
GRHPR Gene-Disease associations (from GenCC):
  • primary hyperoxaluria type 2
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae), Myriad Women’s Health, Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.8).
BP6
Variant 9-37428581-C-T is Benign according to our data. Variant chr9-37428581-C-T is described in ClinVar as Benign/Likely_benign. ClinVar VariationId is 260213.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BS1
Variant frequency is greater than expected in population nfe. GnomAd4 allele frequency = 0.00855 (1302/152192) while in subpopulation NFE AF = 0.0131 (892/68000). AF 95% confidence interval is 0.0124. There are 8 homozygotes in GnomAd4. There are 603 alleles in the male GnomAd4 subpopulation. Median coverage is 33. This position passed quality control check.
BS2
High Homozygotes in GnomAd4 at 8 AR gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
GRHPRNM_012203.2 linkc.493+9C>T intron_variant Intron 5 of 8 ENST00000318158.11 NP_036335.1 Q9UBQ7-1A0A384N605

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
GRHPRENST00000318158.11 linkc.493+9C>T intron_variant Intron 5 of 8 1 NM_012203.2 ENSP00000313432.6 Q9UBQ7-1

Frequencies

GnomAD3 genomes
AF:
0.00857
AC:
1304
AN:
152074
Hom.:
8
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.00205
Gnomad AMI
AF:
0.00110
Gnomad AMR
AF:
0.00701
Gnomad ASJ
AF:
0.00260
Gnomad EAS
AF:
0.000386
Gnomad SAS
AF:
0.00601
Gnomad FIN
AF:
0.0151
Gnomad MID
AF:
0.00633
Gnomad NFE
AF:
0.0131
Gnomad OTH
AF:
0.00814
GnomAD2 exomes
AF:
0.00904
AC:
2219
AN:
245430
AF XY:
0.00950
show subpopulations
Gnomad AFR exome
AF:
0.00155
Gnomad AMR exome
AF:
0.00370
Gnomad ASJ exome
AF:
0.00368
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.0154
Gnomad NFE exome
AF:
0.0132
Gnomad OTH exome
AF:
0.00969
GnomAD4 exome
AF:
0.0116
AC:
16502
AN:
1427638
Hom.:
127
Cov.:
27
AF XY:
0.0115
AC XY:
8155
AN XY:
712030
show subpopulations
African (AFR)
AF:
0.00152
AC:
50
AN:
32986
American (AMR)
AF:
0.00400
AC:
179
AN:
44698
Ashkenazi Jewish (ASJ)
AF:
0.00369
AC:
96
AN:
26000
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39588
South Asian (SAS)
AF:
0.00726
AC:
622
AN:
85686
European-Finnish (FIN)
AF:
0.0149
AC:
703
AN:
47046
Middle Eastern (MID)
AF:
0.0116
AC:
66
AN:
5708
European-Non Finnish (NFE)
AF:
0.0131
AC:
14220
AN:
1086532
Other (OTH)
AF:
0.00953
AC:
566
AN:
59394
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.478
Heterozygous variant carriers
0
776
1552
2329
3105
3881
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
534
1068
1602
2136
2670
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00855
AC:
1302
AN:
152192
Hom.:
8
Cov.:
33
AF XY:
0.00810
AC XY:
603
AN XY:
74422
show subpopulations
African (AFR)
AF:
0.00205
AC:
85
AN:
41518
American (AMR)
AF:
0.00700
AC:
107
AN:
15280
Ashkenazi Jewish (ASJ)
AF:
0.00260
AC:
9
AN:
3468
East Asian (EAS)
AF:
0.000386
AC:
2
AN:
5176
South Asian (SAS)
AF:
0.00581
AC:
28
AN:
4818
European-Finnish (FIN)
AF:
0.0151
AC:
160
AN:
10616
Middle Eastern (MID)
AF:
0.00340
AC:
1
AN:
294
European-Non Finnish (NFE)
AF:
0.0131
AC:
892
AN:
68000
Other (OTH)
AF:
0.00806
AC:
17
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.499
Heterozygous variant carriers
0
67
135
202
270
337
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
20
40
60
80
100
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00645
Hom.:
4
Bravo
AF:
0.00756
Asia WGS
AF:
0.00404
AC:
14
AN:
3478

ClinVar

Significance: Benign/Likely benign
Submissions summary: Benign:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Primary hyperoxaluria, type II Benign:2
Jan 13, 2018
Illumina Laboratory Services, Illumina
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as likely benign is not then subjected to further curation. The score for this variant resulted in a classification of likely benign for this disease. -

Sep 16, 2020
Natera, Inc.
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

not provided Benign:2
Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

not specified Benign:1
-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.80
CADD
Benign
12
DANN
Benign
0.87
PhyloP100
-0.050
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.1
Mutation Taster
=100/0
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs41303225; hg19: chr9-37428578; COSMIC: COSV105894202; COSMIC: COSV105894202; API